Novus Therapeutics (NASDAQ:NVUS) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.18, Fidelity Earnings reports.
Shares of NASDAQ:NVUS traded up $0.01 during midday trading on Thursday, reaching $0.63. The company had a trading volume of 30,100 shares, compared to its average volume of 98,630. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79. The stock’s fifty day moving average price is $0.60 and its 200-day moving average price is $1.09. The stock has a market capitalization of $9.34 million, a P/E ratio of -0.41 and a beta of 2.86. Novus Therapeutics has a one year low of $0.40 and a one year high of $5.21.
NVUS has been the topic of several research analyst reports. ValuEngine cut shares of Novus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Zacks Investment Research cut shares of Novus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and set a $10.00 target price on shares of Novus Therapeutics in a research report on Monday, August 19th.
Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).
Recommended Story: What is a CD ladder?
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.